Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | F2R | P25116 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14454140 | 0.89 | CES2 (0.45) | CES2CES1ALDH1A1MAPTMEN1 | |
| SCHEMBL14454259 | 0.89 | CES2 (0.45) | CES2CES1ALDH1A1MAPTMEN1 | |
| SCHEMBL1162543 | 0.83 | CES2 (0.56) | CES2CES1ALDH1A1MAPTMEN1 | |
| SCHEMBL12934272 | 0.82 | CES2 (0.50) | CES2CES1ALDH1A1MAPTMEN1 | |
| SCHEMBL28910438 | 0.81 | CES2 (0.54) | CES2CES1ALDH1A1MAPTMEN1 | |
| SCHEMBL14384875 | 0.80 | KDM4E (0.44) | CES2CES1ALDH1A1MAPTMEN1 | |
| SCHEMBL2088179 | 0.79 | CES2 (0.52) | CES2CES1ALDH1A1MAPTMEN1 | |
| SCHEMBL11836782 | 0.79 | CES2 (0.57) | CES2CES1ALDH1A1MAPTMEN1 | |
| SCHEMBL14571482 | 0.78 | NLRP3 (0.50) | CES2CES1ALDH1A1MEN1KMT2A | |
| SCHEMBL3121320 | 0.78 | ALDH1A1 (0.57) | CES2CES1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552062-B2 | Methods for the treatment of metabolic disorders such as diabetes | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8487000-B2 | 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis | Wellstat Therapertics Corporation (US) | 2013-07-16 | — | — | US | disclosed |
| US-7863475-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-7851494-B2 | Method for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7547802-B2 | 5-[3-(2,6-Dimethylbenzyloxy)-phenyl]-pent-4-enoic acid ethyl ester; insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis, arteriosclerosis; side effects reduction; orally active | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-06-16 | — | — | US | disclosed |
| US-7329782-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-20080027229-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080021109-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080015209-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-20070265322-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070249696-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070244171-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244141-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244172-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070105958-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20040204417-A1 | Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins | PIERRE FABRE MEDICAMENT (FR) | 2004-10-14 | — | — | US | disclosed |
| EP-1395581-A2 | NOVEL BENZOTHIENYL OR INDOLE DERIVATIVES, PREPARATION AND USE THEREOF AS INHIBITORS OF PRENYL TRANSFERASE PROTEINS | PIERRE FABRE MEDICAMENT (FR) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002098852-A2 | NOVEL BENZOTHIENYL OR INDOLE DERIVATIVES, AND USE THEREOF AS INHIBITORS OF PRENYL TRANSFERASE PROTEINS | PIERRE FABRE MEDICAMENT (FR) | 2002-12-12 | — | — | WO | disclosed |
| EP-0122693-B1 | ANTIFUNGAL DI(AZOLYL)PROPANOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-07-08 | — | — | EP | disclosed |
| US-4625036-A | Antifungal azole compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249696-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | CES2 425/4885CES1 45/4885ALDH1A1 1035/4885 |
| US-20070105958-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | CES2 425/4885CES1 45/4885ALDH1A1 1035/4885 |
| US-20080015209-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | CES2 425/4885CES1 45/4885ALDH1A1 1035/4885 |
| US-20070244171-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | CES2 425/4885CES1 45/4885ALDH1A1 1035/4885 |
| US-20080027229-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | CES2 425/4885CES1 45/4885ALDH1A1 1035/4885 |
| US-20080021109-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | CES2 425/4885CES1 45/4885ALDH1A1 1035/4885 |
| US-20040204417-A1 | Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins | CBR1, CBR3, HCCS | CES2 376/4885CES1 21/4885ALDH1A1 2558/4885 |
| US-20070265322-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | CES2 425/4885CES1 45/4885ALDH1A1 1035/4885 |
| US-20070244172-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | CES2 425/4885CES1 45/4885ALDH1A1 1035/4885 |
| US-20070244141-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | CES2 425/4885CES1 45/4885ALDH1A1 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.